Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell...

Area of Science:

• Immunology
• Oncology
• Metabolomics

Background:

• The glioblastoma microenvironment contains immunosuppressive factors that impair cytotoxic T lymphocyte function.
• Mechanisms by which cancer cells influence the immune system are not fully understood.

Approach:

• Investigated the role of the polyamine metabolite spermidine in the glioblastoma microenvironment.
• Utilized pre-clinical mouse models and patient data to assess spermidine's impact on tumor progression and immune cell function.

Key Points:

• Spermidine is elevated in the glioblastoma tumor microenvironment and drives tumor aggressiveness in an immune-dependent manner.
• Exogenous spermidine reduces CD8+ T cell frequency and alters their phenotype.
• Knockdown of ornithine decarboxylase (spermidine synthesis enzyme) extended survival in mouse models.
• Lower spermidine levels in glioblastoma patients correlated with a more favorable prognosis.

Conclusions:

• Spermidine acts as a cancer cell-derived metabolite promoting glioblastoma progression.
• Spermidine suppresses anti-tumor immunity by reducing CD8+ T cell number and function.
• Targeting spermidine metabolism represents a potential therapeutic strategy for glioblastoma.